Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

March 4, 2021 Auto Bot advance, Clinical Trials, Collaborates, combination, Roche, Study 0

Shots:

  • The companies collaborated to evaluate TPST-1120 + Tecentriq (atezolizumab) and Avastin (bevacizumab) in P-Ib/II study in ~60 patients with advanced HCC prior not treated with HCC
  • Tempest will retain the global rights to develop & commercialize TPST-1120 while Roche will manage the study operations for a global study
  • TPST-1120 is a first-in-class selective PPAR⍺ antagonist with a two-pronged mechanism designed to target both tumor cells directly and suppressive immune cells in the tumor microenvironment. In extensive non-clinical studies, TPST-1120 as a monothx. or in combination with other drugs resulted in reductions of tumor growth and stimulation of durable anti-tumor immunity

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: Business Wire

The post Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma first appeared on PharmaShots.